CytoMed Advances Cell Therapies, Faces Regulatory Hurdles

Ticker: GDTC · Form: 20-F · Filed: Mar 31, 2026 · CIK: 0001873093

Sentiment: mixed

Topics: Biotechnology, Cell Therapy, Gene Therapy, Clinical Trials, Emerging Growth Company, Singapore, Malaysia Manufacturing

TL;DR

**GDTC is a high-risk, high-reward biotech play, betting big on cell therapy trials and a new Malaysian GMP facility, but regulatory hurdles and financing needs loom large.**

AI Summary

CytoMed Therapeutics Ltd (GDTC) filed its 20-F for the fiscal year ended December 31, 2025, indicating its status as an emerging growth company. The company reported 11,828,435 ordinary shares issued and outstanding as of December 31, 2025. While specific revenue and net income figures were not immediately available in the provided excerpt, the filing details significant operational developments, including the establishment of a cGMP Facility in Johor, Malaysia, for manufacturing stem cells and cancer living medicine. Key business changes involve ongoing clinical trials, such as the ANGELICA Trial for CTM-N2D in advanced solid tumors or hematological malignancies, and collaborations like the Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited on December 30, 2024. Risks highlighted include those inherent in developing and commercializing product candidates, obtaining regulatory approvals from authorities like the HSA and FDA, and managing intellectual property. The strategic outlook focuses on advancing its proprietary products like CTM-GDT, CTM-MSC, CTM-N2D, and CTM-NK, and securing additional financing to fund working capital requirements and R&D programs.

Why It Matters

This 20-F filing offers a crucial glimpse into CytoMed Therapeutics' operational progress and strategic direction, particularly its advancements in cell and gene therapy products. For investors, understanding the company's clinical trial progress, manufacturing capabilities in Malaysia, and regulatory pathways in Singapore and the US is vital for assessing future growth potential and market penetration. Employees and customers are directly impacted by the success of these therapeutic developments, which could lead to new treatments and job creation. In the competitive biotech landscape, CytoMed's ability to navigate stringent regulatory environments and secure intellectual property will determine its standing against larger, more established players.

Risk Assessment

Risk Level: high — The risk level is high due to the inherent uncertainties in developing and commercializing product candidates in the biotechnology sector, as explicitly stated in the 'Risk Factors' section. The company's success hinges on obtaining regulatory approvals from bodies like the HSA and FDA, which is a lengthy and often unsuccessful process. Furthermore, the need for additional financing to fund working capital and R&D programs, without specific amounts disclosed in the excerpt, indicates potential dilution or liquidity challenges.

Analyst Insight

Investors should closely monitor CytoMed's progress in its ANGELICA Trial and other R&D programs, paying particular attention to regulatory milestones and any announcements regarding additional financing. Given the high-risk profile, consider this a speculative investment and allocate capital accordingly, perhaps as a small portion of a diversified portfolio.

Key Numbers

Key Players & Entities

FAQ

What are CytoMed Therapeutics' primary product candidates mentioned in the 20-F filing?

CytoMed Therapeutics' primary product candidates include CTM-GDT (allogeneic gamma delta T cell), CTM-MSC (allogeneic umbilical cord derived mesenchymal stem cells), CTM-N2D (CAR-gamma delta T cell), and CTM-NK (cord blood- or peripheral blood-derived natural killer cell proprietary product).

Where is CytoMed Therapeutics' main manufacturing facility located and what does it produce?

CytoMed Therapeutics' main manufacturing facility, the cGMP Facility, is located at 12 Jalan Permas 9/16, Bandar Baru Permas Jaya, 81750 Johor, Malaysia. This facility is equipped for manufacturing stem cells and cancer living medicine.

What is the ANGELICA Trial and what is its purpose for CytoMed Therapeutics?

The ANGELICA Trial is a Phase I trial designed to evaluate allogeneic NKG2DL-targeting chimeric antigen receptor-grafted gamma delta T cells (CTM-N2D) in subjects with advanced solid tumors or hematological malignancies. Its purpose is to assess the safety and efficacy of this proprietary product.

What regulatory bodies are critical for CytoMed Therapeutics' product approvals?

Critical regulatory bodies for CytoMed Therapeutics' product approvals include the Health Sciences Authority (HSA) in Singapore and the United States Food and Drug Administration (FDA). These authorities govern the approval process for therapeutic products and cell, tissue, and gene therapy products.

How many ordinary shares of CytoMed Therapeutics were outstanding as of December 31, 2025?

As of December 31, 2025, there were 11,828,435 of CytoMed Therapeutics' ordinary shares, issued and outstanding. This figure is important for calculating market capitalization and per-share metrics.

What is the significance of CytoMed Therapeutics being an 'emerging growth company'?

Being an 'emerging growth company' under the JOBS Act of 2012 allows CytoMed Therapeutics to take advantage of certain scaled-back disclosure requirements and exemptions from various reporting obligations, potentially reducing compliance costs and administrative burden.

What is the nature of the collaboration between CytoMed Therapeutics and SunAct Cancer Institute Private Limited?

The collaboration between CytoMed Therapeutics and SunAct Cancer Institute Private Limited is formalized through a Business and Research Collaboration Agreement (BRCA) entered into on December 30, 2024. This agreement likely outlines joint efforts in research and development related to cancer therapies.

What are some of the key risks highlighted for CytoMed Therapeutics in its 20-F filing?

Key risks highlighted include the ability to develop and commercialize product candidates, the initiation and results of pre-clinical studies and clinical trials, obtaining regulatory approval, securing additional financing, and protecting intellectual property. These factors can significantly impact future performance.

Who is Choo Chee Kong and what is his role at CytoMed Therapeutics?

Choo Chee Kong is the Chairman and Director of CytoMed Therapeutics Limited. He serves as a key contact person for the company, with his phone and email provided in the filing.

What accounting standards does CytoMed Therapeutics use for its financial statements?

CytoMed Therapeutics prepares its financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (IFRS). This is indicated by the checkmark in the 'Which basis of accounting' section of the 20-F.

Risk Factors

Industry Context

CytoMed Therapeutics operates in the highly competitive and rapidly evolving biotechnology sector, specifically focusing on cell and gene therapies for cancer. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory hurdles. Key trends include advancements in immunotherapy, personalized medicine, and the increasing use of AI in drug discovery and clinical trial design.

Regulatory Implications

The company's success is heavily dependent on navigating complex regulatory pathways with agencies like the HSA and FDA. Obtaining approvals for novel therapies like stem cells and cancer living medicines requires rigorous clinical trial data demonstrating safety and efficacy, posing a significant hurdle and risk.

What Investors Should Do

  1. Monitor clinical trial progress and results for CTM-N2D (ANGELICA Trial) and other pipeline candidates.
  2. Assess the company's ability to secure additional financing.
  3. Evaluate the strategic value and execution of collaborations, such as the SunAct Cancer Institute agreement.
  4. Track the development and operationalization of the cGMP facility in Malaysia.

Key Dates

Glossary

cGMP Facility
Current Good Manufacturing Practice facility. This refers to a system for ensuring that products are consistently produced and controlled according to quality standards. (Indicates the company has established a facility compliant with stringent manufacturing standards required for pharmaceutical products like stem cells and cancer medicines.)
Product Candidates
Potential products that are undergoing research and development, including pre-clinical and clinical testing, before they can be approved for commercial sale. (Refers to CytoMed's pipeline of therapies (e.g., CTM-GDT, CTM-MSC, CTM-N2D, CTM-NK) that are the focus of its R&D efforts and future revenue generation.)
HSA
Health Sciences Authority. The regulatory body in Singapore responsible for the regulation of medicines, innovative therapies, and other health products. (Represents one of the key regulatory bodies from which CytoMed must obtain approval to market its products in Singapore.)
FDA
U.S. Food and Drug Administration. The federal agency responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, etc. (Represents a critical regulatory body for CytoMed, as approval from the FDA is necessary for commercialization in the significant U.S. market.)
ANGELICA Trial
A specific clinical trial being conducted by CytoMed Therapeutics. (Represents a key ongoing clinical study for the company's CTM-N2D product candidate in advanced solid tumors or hematological malignancies, crucial for demonstrating efficacy and safety.)

Year-Over-Year Comparison

As specific financial figures for the fiscal year ended December 31, 2025, were not detailed in the provided excerpt, a direct comparison of revenue growth, margin changes, or other key financial metrics to the previous year's filing is not possible. However, the filing indicates ongoing operational developments, including the establishment of a cGMP facility and new collaborations, suggesting continued investment in R&D and infrastructure. New risks highlighted likely pertain to the progression of these operational advancements and the inherent uncertainties in clinical development and regulatory approvals.

Filing Stats: 4,773 words · 19 min read · ~16 pages · Grade level 20 · Accepted 2026-03-31 08:01:34

Key Financial Figures

Filing Documents

Item 18

Item 17 Item 18 If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No (APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS) Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes No TABLE OF CONTENTS Page PART I 1 ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 1 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 1 ITEM 3. KEY INFORMATION 1 A. [RESERVED] 1 B. CAPITALIZATION AND INDEBTEDNESS 1 C. REASONS FOR THE OFFER AND USE OF PROCEEDS 1 D.

RISK FACTORS

RISK FACTORS 1 ITEM 4. INFORMATION ON THE COMPANY 53 A. HISTORY AND DEVELOPMENT OF THE COMPANY 53 B. BUSINESS OVERVIEW 54 C. ORGANIZATIONAL STRUCTURE 115 D. PROPERTY, PLANTS AND EQUIPMENT 115 ITEM 4A. UNRESOLVED STAFF COMMENTS 115 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 115 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 123 A. DIRECTORS AND SENIOR MANAGEMENT 123 B. COMPENSATION 128 C. BOARD PRACTICES 130 D. EMPLOYEES 131 E. SHARE OWNERSHIP 133 F. DISCLOSURE OF A REGISTRANT'S ACTION TO RECOVER ERRONEOUSLY AWARDED COMPENSATION. 133 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 133 A. MAJOR SHAREHOLDERS 133 B. RELATED PARTY TRANSACTIONS 134 C. INTERESTS OF EXPERTS AND COUNSEL 135 ITEM 8. FINANCIAL INFORMATION 135 ITEM 9. THE OFFER AND LISTING 135 A. OFFERING AND LISTING DETAILS 135 B. PLAN OF DISTRIBUTION 135 C. MARKETS 135 D.

DILUTION

DILUTION 135 E. EXPENSE OF THE ISSUE 135 ITEM 10. ADDITIONAL INFORMATION 136 A. SHARE CAPITAL 136 B. CONSTITUTION OF THE COMPANY 136 C. MATERIAL CONTRACTS 136 D. EXCHANGE CONTROLS 136 E. TAXATION 136 F. DIVIDENDS AND PAYING AGENTS 144 G. 144 H. DOCUMENTS ON DISPLAY 144 I. SUBSIDIARY INFORMATION 144 J. ANNUAL REPORT TO SECURITY HOLDERS 144 ITEM 11.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 144 ITEM 12.

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES 144 PART II 145 ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES 145 ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS 145 A-D. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS 145 E.

USE OF PROCEEDS

USE OF PROCEEDS 145 ITEM 15.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 145 ITEM 16. RESERVED 146 ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT 146 ITEM 16B. CODE OF ETHICS 146 ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES 146 ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES 146 ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS 146 ITEM 16F. CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT 147 ITEM 16G. CORPORATE GOVERNANCE 147 ITEM 16H. MINE SAFETY DISCLOSURE 147 ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 147 ITEM 16J. INSIDER TRADING POLICIES 147 ITEM 16K. CYBERSECURITY 147 PART III 148 ITEM 17.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 148 ITEM 18.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 148 ITEM 19. EXHIBITS 148 i CAUTIONARY This annual report contains certain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on our beliefs and assumptions and on information currently available to us, and include, without limitation, statements regarding our business, financial condition, strategy, results of operations, certain of our plans, objectives, assumptions, expectations, prospects and beliefs and statements regarding other future events or prospects. Forward-looking as the words "believe", "expect", "plan", "intend", "seek", "anticipate", "estimate", "predict", "potential", "assume", "continue", "may", "will", "should", "could", "shall", "risk" or the negative of these terms or similar expressions that are predictions of or indicate future events and future trends. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, the development of the industry in which we operate and the effect of acquisitions on us may differ materially from those made in or suggested by the forward-looking statements contained in this annual report. In addition, even if our results of operations, financial condition and liquidity, the development of the industry in which we operate and the effect of acquisitions on us are consistent with the forward-looking statements contained in this annual report, those results or developments may not be indicative of results or development

View Full Filing

View this 20-F filing on SEC EDGAR

View on Read The Filing